Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society-Reference-Cited by-同舟云学术

Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society

Published:2019 Issue:7 Volume:66 Page:581-586
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Arima Hiroshi¹,Iwama Shintaro²,Inaba Hidefumi³,Ariyasu Hiroyuki³,Makita Noriko⁴,Otsuki Michio⁵,Kageyama Kazunori⁶,Imagawa Akihisa⁷,Akamizu Takashi³

Affiliation:

1. Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan

2. Department of Endocrinology and Diabetes, Nagoya University Hospital, Nagoya 466-8560, Japan

3. The First Department of Medicine, Wakayama Medical University, Wakayama 641-8509, Japan

4. Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo 113-8655, Japan

5. Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan

6. Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan

7. Department of Internal Medicine (I), Osaka Medical College, Takatsuki 569-8686, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/66/7/66_EJ19-0163/_pdf

Reference28 articles.

1. 1 Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158–168.

2. 2 Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, et al. (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40: 17–65.

3. 3 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, et al. (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36: 1714–1768.

4. 4 Higham CE, Olsson-Brown A, Carroll P, Cooksley T, Larkin J, et al. (2018) Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7: G1–G7.

5. 6 Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, et al. (2016) Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186: 3225–3235.

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolated Adrenocorticotropic Hormone (ACTH) Deficiency as an Immune-Related Adverse Event Following Combination Immune Checkpoint Inhibitor Therapy;Cureus;2024-06-21

2. Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event;Immunotherapy;2024-06-18

3. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study;Cancer Immunology, Immunotherapy;2024-06-04

4. From tumor to tolerance: A comprehensive review of immune checkpoint inhibitors and immune-related adverse events;Asia Pacific Allergy;2024-05-30

5. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes;Frontiers in Endocrinology;2024-05-22